about
Incidence of Crohn's Disease in Four Counties in Southeastern Norway, 1990–93 A Prospective Population-Based StudyQuality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity, reliability and sensitivity to change of the Norwegian version of IBDQ.Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern NorwayElevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function.Psychometric limitations of the 13-item Sense of Coherence Scale assessed by Rasch analysis.Seasonal variations in the onset of ulcerative colitisEpidemiology of inflammatory bowel disease--methodological considerations.Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis.Worries and Concerns among Inflammatory Bowel Disease Patients Followed Prospectively over One YearChronic fatigue is associated with increased disease-related worries and concerns in inflammatory bowel disease.Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort.Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis.The Use of Complementary and Alternative Medicine among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of LifeSense of coherence in patients with inflammatory bowel diseaseNeed for standardization in population-based quality of life studies: a review of the current literature.Hospitalisations and surgery in Crohn's disease.Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study.Complementary and alternative medicine in patients with inflammatory bowel disease: the results of a population-based inception cohort study (IBSEN).Geographical variability and environmental risk factors in inflammatory bowel disease.What have we learnt about the role of the environment and natural course of IBD in the new millennium? 20-year follow-up of the IBSEN cohort.Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue.Comparison of the Multiattribute Utility Instruments EQ-5D and SF-6D in a Europe-Wide Population-Based Cohort of Patients with Inflammatory Bowel Disease 10 Years after Diagnosis.Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population.Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease.Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis: Results from the IBSEN Study.Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990-1993.Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis.Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring.Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study).Patients' perceptions of quality of care and follow-up in inflammatory bowel disease.Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study.Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation.The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93.Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time.[Natural products can be hazardous to health]Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission.Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease.Phenotype at diagnosis predicts recurrence rates in Crohn's disease.
P50
Q22241265-61BA7345-B105-439D-8740-B10EB65B53C8Q30743333-8E2FBAF3-4465-4D81-A4CE-6E94EF5C0412Q33617865-C37B4E20-6A2D-4099-BAE2-F5E3DCCCBE8BQ33731986-5F81765E-33CD-497D-83CA-2F91228EED4CQ33781448-C805BF47-0136-4745-84B0-48D25A742C35Q34409427-27F19FD5-B734-49F0-87BA-EEF4E73B0B90Q34740684-98B8D064-9D88-4F38-941D-6CC8423BD269Q35135991-155D57D5-4DCA-47DB-8C6B-04C79C9F01F0Q35200114-482508C4-C848-40E6-8EBF-71E19160F347Q35725877-C64B597B-D170-46E5-8C44-4E9AC5D8E716Q35760428-85C7EDC0-1A2A-43A8-A020-991BD4D75C00Q35761403-95CD6DD9-2A5B-45CD-84C6-5D168DEE27E1Q37492485-C9CE6CDB-B998-4970-85A6-BD3B46DF19F3Q37542550-9F36A475-F83D-4A90-AFCE-F7D786FB68ACQ37564287-5C60EE3F-EC16-4647-9912-D5AB7F78FB63Q37977910-77E3EA8C-83B7-439B-91E9-58A293820AA3Q37991442-07753C03-255B-4C62-BC38-A89BEC40639AQ37992245-F1B5EAF2-9F8C-48B6-BB42-3F54A053FBD5Q38075524-C193CECD-A2F4-4EA6-A98D-EB83E3494F6AQ38296792-A806C9E0-C35F-41B0-B150-926FE82A4AFFQ38621244-BF06528F-C8B6-4B72-9AC5-257DC3751F50Q39388069-B9B67499-878F-4869-9CF8-777E7A3A85BDQ39414345-5305342E-95E8-4486-A15D-A6A09A784B31Q39656708-D02D2344-9220-469A-88A6-504E9384184AQ39749465-D86E95A2-DFB3-4E67-9194-F10790C5119AQ39838823-F13ED4CF-BA6D-441A-9C0A-12EEB42B2C06Q39912824-C91545C4-3DEC-423A-91B7-ABFF04364287Q39942595-5DB51375-E97B-4661-9062-FD1DFCBED960Q40148875-CE40D8D5-5156-403F-96A9-FE90A72B0F3CQ40243918-B4C4EC9E-76CC-4124-A3B0-FCC5F2532C47Q40349590-B0DD2852-851D-4FDE-9B62-2B3AF81ADA25Q40473404-584DBDE0-7E19-40CD-A508-E56C1DE6FACEQ40753393-3B334F8D-E125-44AA-969F-7C8AFFB8EB08Q40787355-DBBBAF81-1A51-41CF-8243-F11481D0AF73Q41635928-7BEE5E4F-87DF-42E5-8A65-92E25622453FQ41671372-54E72958-2F1D-441D-97D6-5FB93AE46865Q41956073-B67B8C7C-833B-4827-82CB-54977456DB35Q42040867-D75E8EFD-FE12-4472-B13B-2DF684326928Q42620808-6269B9F6-7BD1-441C-A651-4BF3874FE4F7Q42844583-E93FE339-FECD-4A3C-8B0D-8C99FF2E5862
P50
description
Noors onderzoeker
@nl
Norwegian professor
@en
norsk professor
@nb
name
Bjorn Moum
@sq
Bjørn Moum
@da
Bjørn Moum
@de
Bjørn Moum
@en
Bjørn Moum
@es
Bjørn Moum
@fr
Bjørn Moum
@nb
Bjørn Moum
@nl
Bjørn Moum
@nn
Bjørn Moum
@sl
type
label
Bjorn Moum
@sq
Bjørn Moum
@da
Bjørn Moum
@de
Bjørn Moum
@en
Bjørn Moum
@es
Bjørn Moum
@fr
Bjørn Moum
@nb
Bjørn Moum
@nl
Bjørn Moum
@nn
Bjørn Moum
@sl
altLabel
Bjørn A Moum
@en
Bjørn A. Moum
@en
Bjørn Allan Moum
@en
Bjørn Allan Moum
@nb
prefLabel
Bjorn Moum
@sq
Bjørn Moum
@da
Bjørn Moum
@de
Bjørn Moum
@en
Bjørn Moum
@es
Bjørn Moum
@fr
Bjørn Moum
@nb
Bjørn Moum
@nl
Bjørn Moum
@nn
Bjørn Moum
@sl
P2038
Bjorn_Moum
P21
P214
176149066690465602680
P27
P31
P496
0000-0002-5884-4543
P569
1952-01-01T00:00:00Z
P734
P7859
viaf-176149066690465602680